Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Long-read profiling of structural variants reveals mechanisms of chemo-resistance and prognostic heterogeneity in acute lymphoblastic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

MXMA Xiao-fang

Discussion

Loading...

Member takes

Overview

Long-read sequencing reveals distinct chemo-resistance mechanisms in acute lymphoblastic leukemia subtypes, highlighting the role of structural variants and PAX5.

Key Points

  • Chemo-resistance mechanisms identified in acute lymphoblastic leukemia using long-read sequencing, enhancing treatment strategies.
  • Average 6,557 structural variants found per sample across 14 patient-derived xenografts, with significant diversity in drug responses.
  • Analysis via next generation sequencing and HiPore-C revealed transcriptional activity influences structural variant effects on glucocorticoid sensitivity.
  • Discoveries underscore the potential for precision medicine approaches in stratifying acute lymphoblastic leukemia treatment plans.

Cite This Study

MA Xiao-fang (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236deabhttps://doi.org/10.1182/blood-2025-1585
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical value of advanced genomic testing in adult Philadelphia-negative B-ALL: Results from the CZ national leukemia study group (CELL)2025
  2. 2Sensitive detection of novel structural variants and 3D chromosome conformation reveals likely novel drivers including enhancer hijacking in AML2025
  3. 3A single cell multiomic approach to dissect immunophenotypic plasticity in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) pediatric patients2025
  4. 4Integrated multi-omic analysis reveals novel subtype-specific regulatory interactions in pediatric B-cell acute lymphoblastic leukemia2025
  5. 5Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial2025 · 2 citations